A Feasibility And Toxicity Study Of Vaccination With HSP70 For The Treatment Of Chronic Myelogenous Leukemia In Chronic Phase
- Determine the feasibility of vaccination with autologous heat shock protein 70 in
patients with chronic phase chronic myelogenous leukemia.
- Determine the toxicity of this vaccination in these patients.
OUTLINE: Patients undergo leukapheresis to obtain peripheral mononuclear cells (PMNCs). Heat
shock protein 70 (HSP70) is derived from the autologous PMNCs. Patients receive HSP70
intradermally once weekly for 8 weeks.
Patients are followed for 2 weeks.
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
Primary Purpose: Treatment
Zihai Li, MD, PhD
University of Connecticut Health Center
United States: Federal Government
|University of Connecticut Health Center||Farmington, Connecticut 06360-7106|